1. Chemotherapy for advanced non-small cell lung cancer: who, what, when, why?;Bunn;JCO,2002
2. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials;Shepherd;Semin Oncol.,2001
3. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy;Hanna;J. Clin. Oncol.,2004
4. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, et al. NCIC CTG, Kingston, ON, Canada A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proceedings of ASCO 2004, Abstract 7022
5. Chemotherapy in advanced non-small cell lung cancer: indication, intensity, and duration;Booton;Curr. Opin. Oncol.,2002